Pneumonia

FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI

Retrieved on: 
Friday, December 15, 2023
Biotechnology, General Health, FDA, Health, Pharmaceutical, MSD, Medicine, DSM-IV codes, PD-L1, NYSE, Potassium, Food, Progression-free survival, RECIST, Merck & Co., Head, Pneumonia, Blood transfusion, Dana–Farber Cancer Institute, Risk, Lymphocyte, Hypoxia, Everolimus, Bleeding, IMDC, Fatigue, Sepsis, Patient, Pregnancy, PFS, Effectiveness, Belzutifan, Week, VHL, VEGF, RCC, COVID-19, PD-1, Creatinine, TKI, ORR, Harvard Medical School, Death, Anemia, Fatal, Sodium, Hospital, Pleural effusion, HIV disease progression rates, MRK, Pharmaceutical industry, Birth control, Merck

Also, WELIREG showed an objective response rate (ORR) of 22% (n=82) (95% CI, 18-27) versus 4% (n=13) (95% CI, 2-6) for everolimus.

Key Points: 
  • Also, WELIREG showed an objective response rate (ORR) of 22% (n=82) (95% CI, 18-27) versus 4% (n=13) (95% CI, 2-6) for everolimus.
  • Patients could have received up to three prior treatment regimens and were required to have measurable disease per RECIST v1.1.
  • Dose reductions of WELIREG due to an adverse reaction occurred in 13% of patients.
  • Adverse reactions that required dose reduction in ≥1% of patients were hypoxia (5%) and anemia (3.2%).

US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer

Retrieved on: 
Thursday, December 14, 2023
Children, FDA, Health, General Health, Pharmaceutical, Oncology, Research, Family, Consumer, Science, Parenting, Neuroblastoma, Tenderness, Urine, Pneumonia, Huber loss, Somatic symptom disorder, Patient, Otitis media, Diagnosis, Tiffany Aching, Bruise, Liver, Chills, Hospital, Hearing loss, Vomiting, Food, Chair, American Cancer Society, EFS, Nose, Mortality, Multimedia, Division, Hematology, Pennsylvania State University, Blood, Diarrhea, Kool-Aid, Bleeding, Nausea, Development, Skin infection, Shivering, Urinary tract infection, Cough, Consortium, Risk, Sinusitis, Humble, Texas, Pain, Skin, Eflornithine, Hope, Upper respiratory tract infection, Disease, Abdomen, Tablet, Pediatric Hematology and Oncology, Sneeze, MD, Death, Immunotherapy, Pharmaceutical industry, Medical device, Nursing, Birth control, Phosphorus, Fever, USWM

High-risk neuroblastoma is a challenging disease, with a high mortality rate driven primarily by the risk of relapse after achieving remission.

Key Points: 
  • High-risk neuroblastoma is a challenging disease, with a high mortality rate driven primarily by the risk of relapse after achieving remission.
  • US WorldMeds partnered with the Beat Childhood Cancer Research Consortium at Penn State University, which conducted the preclinical and clinical research to help advance this vital therapy.
  • The Consortium represents a group of over 50 hospitals that offer collaboration through a network of childhood cancer clinical trials.
  • “We are thankful for the dedication of our partners, specifically the Beat Childhood Cancer Research Consortium, who work tirelessly to improve treatment outcomes for pediatric cancer patients.

Petzey Addresses Unidentified Respiratory Illness Spreading Amongst Dogs

Retrieved on: 
Wednesday, December 13, 2023
Family, Health, Consumer, Infectious Diseases, Pets, Veterinary, Pet, Immune system, Pneumonia, Infection, Azithromycin, Chloramphenicol, Risk, Vaccination, Bordetella, Steroid, Weakness, Dehydration, Cold, Therapy, Human, Wheeze, Parent, Somatic symptom disorder, Dog, Lethargy, Vaccine, Doxycycline

Petzey , the leading on-demand mobile pet telehealth and wellness app, is addressing the recent outbreak of an unidentified respiratory illness affecting dogs across the country, from Oregon to Florida.

Key Points: 
  • Petzey , the leading on-demand mobile pet telehealth and wellness app, is addressing the recent outbreak of an unidentified respiratory illness affecting dogs across the country, from Oregon to Florida.
  • The condition, which has yet to be officially named, presents symptoms similar to known respiratory viruses and subsequent bacterial infections.
  • The illness can progress to pneumonia, posing a severe health risk.
  • Dr. Danny Cox, Chief Veterinary Medical Officer at Petzey, states, “What we understand about this new respiratory bug is its resemblance to other respiratory viruses like last year’s canine flu, canine parainfluenza, and treatable bacterial infections such as bordetella and pneumococcal pneumonia.

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

Retrieved on: 
Tuesday, December 12, 2023
Cardiology, Biotechnology, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, VLP, Disease, COPD, Acquisition, Heart, AstraZeneca, RSV, Food, Virus-like particle, Security (finance), Incidence, Pneumonia, Human, Risk, US Foods, Protein, Mortality, Vaccination, Fast track (FDA), Patient, Urinary tract infection, Letter, Death, Vaccine, Hepatitis, Infection, Immune Therapy Holdings, University, Virus, Communication, SARS-CoV-2, VWAP, Viral pneumonia, Asthma, Immunity (medical), Schedule, Respiratory syncytial virus, Pharmaceutical industry

Iskra Reic, Executive Vice President, Vaccines & Immune Therapies, AstraZeneca, said: “This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV.

Key Points: 
  • Iskra Reic, Executive Vice President, Vaccines & Immune Therapies, AstraZeneca, said: “This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV.
  • Icosavax’s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
  • In Icosavax’s Phase II trial, IVX-A12 showed robust immune responses across RSV and hMPV antibodies, reconfirming previous immunogenicity data seen in the smaller Phase I trial.
  • The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial.

Respiratory Disease Vaccine Market Size, Share & Trends Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 12, 2023
Health, Pharmaceutical, Viral, Pfizer, Research, RSV, Market, Combination, Pneumonia, Incidence, Ageing, Urinary tract infection, Investment, Risk, Traction, Vaccination, Respiratory disease, FDA, Vaccine, USD, Influenza, COVID-19, Infection, Growth, SARS-CoV-2, Pharmaceutical industry

The "Respiratory Disease Vaccine Market Size, Share & Trends Analysis Report By Type (Viral, Bacterial, Combination), By Age Group, By Infection (COVID-19, Influenza), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Disease Vaccine Market Size, Share & Trends Analysis Report By Type (Viral, Bacterial, Combination), By Age Group, By Infection (COVID-19, Influenza), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global respiratory disease vaccine market size is expected to reach USD 70.30 billion by 2030, expanding at a CAGR of 1.21% from 2023 to 2030
    The growth of the respiratory disease vaccine market is attributable to increasing awareness associated with the importance of vaccination, the rising incidence of respiratory infections, and advancements in vaccine technology.
  • Moreover, the COVID-19 pandemic has brought significant traction to the importance of respiratory vaccines which has further accelerated the market.
  • In recent years, the respiratory vaccine market has witnessed substantial growth attributed to advancements in vaccine technology, specifically in the development of vaccines targeting SARS-CoV-2.

United States Mobile Medical Imaging Service Market Insights Report 2024: Market to Reach $548.94 Million by 2029 with KMG, DMS Health, and Shared imaging Dominating - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 12, 2023
Radiology, Hospitals, Health, Medical Devices, Abdominal ultrasonography, Ambulatory Surgery Center Association, Pneumonia, Prenatal care, Risk, Patient, COVID-19, Infection, Diagnosis, Growth, Palliative care, Accident, Medical imaging

The "U.S Mobile Medical Imaging Service Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S Mobile Medical Imaging Service Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.
  • This will increase the demand for mobile medical imaging as the separate living facilities engage with mobile imaging service providers.
  • The US market for mobile medical imaging services has experienced significant growth, especially due to the increased demand driven by the COVID-19 pandemic.
  • ASCs have shifted hospital outpatient settings and increasingly rely on mobile medical imaging services, highlighting their importance in modern healthcare.

Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bristol Myers Squibb, Safety, NYSE, Non-Hodgkin lymphoma, Pneumonia, ASH, Ikaros, Rituximab, Patient, Cell, Thrombocytopenia, BMY, Lymphoma, Death, CMR, DL, Neutropenia, ORR, Anemia, Society, NK, Febrile neutropenia, Pharmaceutical industry, Fever, DL-1, Hematology

Bristol Myers Squibb (NYSE: BMY) announced the results of two early studies evaluating combinations of potential first-in-class CELMoD™ agent golcadomide in non-Hodgkin lymphomas.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) announced the results of two early studies evaluating combinations of potential first-in-class CELMoD™ agent golcadomide in non-Hodgkin lymphomas.
  • These data are being presented in separate posters ( #4459 , #4496 , #1631 ) at the 2023 American Society of Hematology (ASH) Annual Meeting from December 9-12.
  • “In the studies being presented at ASH 2023, golcadomide has shown potential warranting further evaluation in patients with first-line and previously treated large B-cell lymphomas.
  • There were 4 deaths on treatment during the study with one considered related to the study treatment.

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Retrieved on: 
Sunday, December 10, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Molecular Pharmacology, Fever, Associate, Azacitidine, Hypotension, Safety, CCR, Spacecraft, Pneumonia, ASH, University, Cytopenia, Disease, Cellular, Constipation, Fatigue, Mortality, Penile ultrasonography, Patient, IMGN, DNA, MRD, Medical Affairs Bureau, Pharmacokinetics, Peripheral edema, Flow cytometry, Capillary leak syndrome, MD, Diarrhea, Cancer, Nausea, Survival, Drug resistance, Transplant, AML, Apoptosis, MD Anderson Cancer Center, Society, ImmunoGen, Hypokalemia, Hypophosphatemia, Venetoclax, Rare-earth element, Pharmaceutical industry, Birth control, Vaccine, Medicinal plants, Research

These findings will be presented in a poster session at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.

Key Points: 
  • These findings will be presented in a poster session at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.
  • “The MRD negativity rates, which are indicative of a deep remission, are particularly promising in the treated patient population.
  • Response rates and MRD negativity were numerically comparable between cohorts 1 and 2, despite differences in the venetoclax schedule.
  • We look forward to continuing to expand our cohort of newly diagnosed unfit patients to inform the development path for pivekimab in AML.”
    ImmunoGen is also presenting two preclinical posters at ASH.

DoseMe Adds Cefepime to Its Model-informed Precision Dosing Platform

Retrieved on: 
Monday, December 4, 2023
Technology, Biotechnology, FDA, Health, Pharmaceutical, Other Science, University, Research, Software, Infectious Diseases, Education, Health Technology, Science, Data Management, Hospice and palliative medicine, Neutropenia, Genetically modified bacteria, Cefepime, BCPS, TDM, Pneumonia, Doctor of Pharmacy, Risk, Fungal infection, Serum, Patient, Infection, Midwestern University, Pharmacokinetics, University of Illinois Chicago, Kidney, Owen Scheetz, Bacteria, Creatinine, Neurotoxicity, EGFR, Bias, Postgraduate education, Skin, Therapeutic drug monitoring, Pharmaceutical industry, Pharmacology, Dosem

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the availability of its Cefepime model.

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the availability of its Cefepime model.
  • His research continues to highlight three keys to infectious disease monitoring - real time beta lactam monitoring, therapeutic drug monitoring and precision dosing.
  • “Similar to many beta lactam treatments, Cefepime displays a large amount of variability between patients and having DoseMeRx enables precision dosing,” stated Scheetz.
  • Greater recognition of the benefits of Model-informed Precision Dosing (MIPD) software for enhancing TDM and dosing precision necessitates thorough validation of models and reassessment of current workflows.

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma

Retrieved on: 
Friday, December 8, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Multiple myeloma, Lymphocytopenia, Fever, Bispecific monoclonal antibody, NYSE, Cytokine release syndrome, PFE, European Medicines Agency, Rash, European Commission, Pneumonia, Upper respiratory tract infection, CRS, Risk, Febrile neutropenia, Fatigue, EMA, Civil service commission, Patient, Sepsis, Thrombocytopenia, Probability, Periodic breathing, Appetite, CHMP, B-cell maturation antigen, Injection site reaction, Committee, Neutropenia, Diarrhea, Nausea, Arthralgia, RRMM, Anemia, BCMA, Immunotherapy, Hypokalemia, Urinary tract infection, Inc., HIV disease progression rates, Vaccine, Pharmaceutical industry, Pfizer, Nature Medicine

Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab).

Key Points: 
  • Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab).
  • "More than 50,000 Europeans are diagnosed with multiple myeloma each year, and too often, they face relapse and treatment resistance,” said Chris Boshoff, Chief Oncology Research and Development Officer and Executive Vice President, Pfizer.
  • The conditional marketing authorization for ELREXFIO is valid in all 27 EU member states as well as Iceland, Liechtenstein, and Norway.
  • This authorization follows the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation for a conditional marketing authorization on October 12, 2023.